<DOC>
	<DOCNO>NCT00780416</DOCNO>
	<brief_summary>This study evaluate efficacy safety MP-424 Peginterferon Alfa-2b ( PEG-IFN ) Ribavirin ( RBV ) treatment-naïve patient ( Genotype 1 ) hepatitis C .</brief_summary>
	<brief_title>Efficacy Safety MP-424/Peginterferon Alfa-2b/Ribavirin Combination Treatment-Naïve Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Genotype 1 , chronic hepatitis C Treatmentnaïve ( patient receive previous interferon base treatment hepatitis C ) Able willing follow contraception requirement Cirrhosis liver hepatic failure Hepatitis B surface antigenpositive HIV antibodiespositive History , concurrent hepatocellular carcinoma History , concurrent depression , schizophrenia ; suicide attempt past Pregnant , lactating , suspect pregnant patient , male patient whose female partner pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>Peginterferon Alfa-2b</keyword>
	<keyword>Ribavirin</keyword>
</DOC>